Cargando…
A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
Temozolomide (TMZ) is the first-line chemotherapy drug that has been used to treat glioma for over a decade, but the benefits are limited by half of the treated patients who acquired resistance. Studies have shown that glioma TMZ resistance is a complex process with multiple factors, which has not b...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324762/ https://www.ncbi.nlm.nih.gov/pubmed/32656078 http://dx.doi.org/10.3389/fonc.2020.00897 |